National Survey of Lung Cancer in Korea, 2005.
- Author:
Young Chul KIM
1
;
Yong Soo KWON
;
In Jae OH
;
Kyu Sik KIM
;
Sun Young KIM
;
Jeong Seon RYU
;
Ho Kee YUM
;
Suk Joong YONG
;
Kwan Ho LEE
;
Chang Geol LEE
;
Sang Yeub LEE
;
Sung Yong LEE
;
Maan Hong JUNG
;
Eun Taik JEONG
;
Kwang Ho IN
Author Information
- Publication Type:Original Article
- Keywords: Lung cancer; Registry; Survival; Korea
- MeSH: Adenocarcinoma; Age Distribution; Aged; Carcinoma, Large Cell; Chest Pain; Cough; Diagnosis; Drug Therapy; Dyspnea; Hemoptysis; Hoarseness; Humans; Incidence; Korea*; Lung Neoplasms*; Lung*; Male; Multivariate Analysis; Small Cell Lung Carcinoma; Weight Loss
- From:Journal of Lung Cancer 2007;6(2):67-73
- CountryRepublic of Korea
- Language:Korean
- Abstract: PURPOSE : Lung Cancer has been the leading cause of cancer deaths in South Korea since the year 2000, and its incidence continues to rise. Here we report the result of national survey of lung cancer conducted by Korean association for the study of lung cancer (KASLC). MATERIALS AND METHODS : A total of 8,788 lung cancer patients diagnosed in 2005 were registered using a web based case report form issued to hospitals equipped with more than 400 beds. RESULTS : The age distribution ranged from 11 to 105 years (64.7+/-0.7 years), 75.8% (6,664) of the patients were male and 28.9% of patients were never smokers. Subjective symptoms at the time of diagnosis included coughing (3,350 patients), dyspnea (2,105), chest pain (1,067), hemoptysis (805), weight loss (789), general weakness (498) and hoarseness (190), while 12% (1,015) of patients had no subjective symptoms. Of the carcinomas grouped into non-small cell lung carcinoma (NSCLC), adenocarcinoma including bronchoalveolar cell carcinoma (1.3%) was the most frequent (36.1%) histopathologic type, followed by squamous cell lung carcinoma (32.1%), large cell carcinoma (1.5%), unclassified non-small cell carcinoma (13.2%) and others (3.7%). In addition, 13.5% of all of the patients were afflicted with small cell lung carcinoma (SCLC). The stage at diagnosis was IA (7.3%), IB (10.2%), IIA (1.3%), IIB (6.1%), IIIA (12.8%), IIIB (21.6%), and IV (40.6%) in the NSCLC group. In SCLC group, 44.6% of the patients were in the limited stage, while 55.4% of the patients were in the extensive stage. The initial treatments included surgery (22.1%), radiation therapy (7.8%), chemo-radiation therapy (5.4%) and chemotherapy (38%), however, 26.6% of the patients were transferred or recorded to have supportive care only. Therefore we compared the outcomes of the Treatment Group (TG, 73.4%) and the Supportive Group (SG, 26.6%). The median survival time (MST) in months (m) was 28 (95% confidence interval 26.5~29.5 m). Multivariate analysis indicated that the independent prognostic factors for NSCLC were age, gender, ECOG PS score, stage, histopathologic type, and treatment or supportive care. In the SCLC group, age, PS score, stage, treatment or supportive care were significant prognostic factors. The TG group showed significantly superior survival when compared to the SG group, even in patients with stage IV disease and in patients that were >75 years old. CONCLUSION : Adenocarcinoma was found to be the most frequent histopathologic type, and active treatments were found to improve the survival of patients with lung cancer, even when they were in advanced stages or elderly
